Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 and up

Comparing single and dual antiplatelet therapies after heart surgery

Official title: Single Versus Dual Antiplatelet Therapy in Patients With Incomplete Revascularization After Coronary Artery Bypass Graft Surgery

Run by Campus Bio-Medico University · NCT03789916 · Data updated 2026-11-12

This study tests whether taking one or two types of blood-thinning medications after heart surgery helps patients who haven't had all their blood vessels fixed live longer and healthier.

More Coronary Artery Disease trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment800 (estimated)
SponsorCampus Bio-Medico University
Academic / other
Locations1 site (Rome)
StatusRecruiting
StartedJanuary 2, 2019
Main results expectedAugust 1, 2021
Study endsDecember 31, 2026
Registry record updatedJuly 21, 2022
Trial IDNCT03789916 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients who have undergone CABG and have been identified as having incomplete myocardial revascularization.

Probably not a fit

Patients with acute coronary syndrome within the last 12 months or those who cannot tolerate the medications involved will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study compares the effectiveness of single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) in patients who have undergone coronary artery bypass grafting (CABG) and have incomplete revascularization. Participants will be randomly assigned to receive either SAPT or DAPT before hospital discharge, with DAPT being administered for 12 months. The primary goal is to evaluate cardiac-related mortality five years after discharge.

Why it matters

Potential benefit: If successful, this study could provide insights into the optimal antiplatelet therapy for patients with incomplete revascularization, potentially improving long-term cardiac outcomes.

How similar studies have gone: Previous studies have explored antiplatelet therapies in similar contexts, but this specific comparison of SAPT versus DAPT in incomplete revascularization is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* patients undergoing CABG, ± cardiopulmonary bypass, ± any associated cardiac procedures (valve replacement,...)
* incomplete myocardial revascularization, defined by anatomic or functional criteria
* obtained informed consent

Exclusion Criteria:

* acute coronary syndrome \< 12 months from surgery
* dual antiplatelet therapy at hospital admission
* planned procedure to complete myocardial revascularization (e.g. hybrid approach)
* intolerance / unable to take acetylsalicylic acid or ticagrelor
* preoperative atrial fibrillation
* impaired compliance
* planned pregnancy
* history of gastrointestinal bleeding
* chronic kidney disease (eGFR \< 30 mL/min/1.73 m2)
* chronic liver disease
* severe heart failure at hospital admission
* active malignancy
* alcohol abuse
* any clinical condition not compatible with the treatment

Exit Criteria:

* postoperative atrial fibrillation requiring anticoagulation
* postoperative hemorrhagic events (stroke, GI bleeding)
* occurrence of contraindications to acetylsalicylic acid or ticagrelor
* surgical treatment requiring DAPT withdrawn
* patient decision

Where it's running

  • Università Campus Bio-Medico di Roma
    Rome, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.